B+
Bull case
25%
Probability
Target price
$2.40
+34.1% vs current
CDIO
Cardio DiagnosticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.90
+6.1% vs current
B-
Bear case
30%
Probability
Target price
$1.00
-44.1% vs current
AI sentiment snapshot
Latest data as of 2026-07-12
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+47.9
Score
AI commentary
Deterministic scoring is modestly positive, but the investable read-through still looks like a cautious monitoring view. Recent news flow is active yet largely promotional NewMediaWire-style awareness content rather than a new filing-backed commercial inflection. Primary sources remain more important than the headlines here, and those sources still point to low revenue, continuing burn, reimbursement dependency, and dilution risk. With no usable analyst-revision set and only loose microcap peers, confidence should stay capped despite stronger evidence quality than a typical low-coverage name.
RankAlpha Sentiment Codex - 2026-07-12
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15eventQ1 2026 filing kept dilution and cash burn as the main near-term factsMedium impact
The 2026-05-15 10-Q showed just $2,680 of Q1 revenue, a $1.79M net loss, and $1.56M of operating cash use, while also disclosing 1,133,418 additional shares sold after year-end under the ATM for $3.69M net proceeds; that keeps financing access and dilution ahead of commercialization as the dominant near-term driver [#10-Q-2026-05-15] [#SEC-10Q-2026-05-15].
2026-06-30catalystReimbursement and out-of-network billing progress still need hard confirmationHigh impact
Management said in the 10-K that it expected out-of-network claims capability to begin in Q2 2026, while the February 19, 2026 investor presentation said Medicare coverage work was still ongoing and commercial-payer pilots were being pursued; company-source confirmation that billing capability or payer traction actually converted into reimbursable volume remains the key missing proof point [#10-K-2026-03-13] [#8-K-2026-02-19].
2026-12-31catalystCLIA lab launch and India partnerships must translate into repeatable revenueHigh impact
Company materials point to a newly launched internal CLIA lab with an initial ~30% COGS reduction and increased testing capacity, plus India partnerships with Aimil Ltd and Dr. Lal PathLabs, but the equity case still depends on those operating steps converting into sustained test volume rather than remaining infrastructure and awareness milestones [#8-K-2026-02-19] [#10-K-2026-03-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-12 • Updated nightlySource: Internal modelMethodology